Comment le stress chronique influence-t-il les corticotropes ?
Le stress chronique peut entraîner une surproduction d'ACTH et des troubles associés.
Stress chroniqueACTHTroubles associés
#3
Y a-t-il des prédispositions hormonales aux troubles corticotropes ?
Certaines conditions hormonales, comme le syndrome de Cushing, peuvent être prédisposantes.
Syndrome de CushingPrédispositions hormonalesTroubles corticotropes
#4
Quel rôle joue l'âge dans les troubles corticotropes ?
L'âge avancé peut augmenter le risque de développer des troubles hypophysaires.
ÂgeTroubles hypophysairesRisque
#5
Les femmes sont-elles plus à risque que les hommes ?
Oui, certaines études montrent que les femmes sont plus susceptibles de développer des troubles corticotropes.
Sexe fémininRisqueTroubles corticotropes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Cellules corticotropes : Questions médicales les plus fréquentes",
"headline": "Cellules corticotropes : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Cellules corticotropes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-20",
"dateModified": "2026-02-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Cellules corticotropes"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cellules épithéliales",
"url": "https://questionsmedicales.fr/mesh/D004847",
"about": {
"@type": "MedicalCondition",
"name": "Cellules épithéliales",
"code": {
"@type": "MedicalCode",
"code": "D004847",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "A11.436"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Cellules corticotropes",
"alternateName": "Corticotrophs",
"code": {
"@type": "MedicalCode",
"code": "D052680",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Anthony P Heaney",
"url": "https://questionsmedicales.fr/author/Anthony%20P%20Heaney",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. aheaney@mednet.ucla.edu."
}
},
{
"@type": "Person",
"name": "Michael J Shipston",
"url": "https://questionsmedicales.fr/author/Michael%20J%20Shipston",
"affiliation": {
"@type": "Organization",
"name": "Centre for Discovery Brain Sciences, Edinburgh Medical School: Biomedical Sciences, University of Edinburgh, Edinburgh, United Kingdom."
}
},
{
"@type": "Person",
"name": "Marily Theodoropoulou",
"url": "https://questionsmedicales.fr/author/Marily%20Theodoropoulou",
"affiliation": {
"@type": "Organization",
"name": "Medizinische Klinik und Poliklinik IV, LMU Klinikum,, LMU Munich, München, Germany."
}
},
{
"@type": "Person",
"name": "Kazunori Kageyama",
"url": "https://questionsmedicales.fr/author/Kazunori%20Kageyama",
"affiliation": {
"@type": "Organization",
"name": "Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan."
}
},
{
"@type": "Person",
"name": "Kanako Niioka",
"url": "https://questionsmedicales.fr/author/Kanako%20Niioka",
"affiliation": {
"@type": "Organization",
"name": "Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036-8562, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Silent Corticotroph Staining Pituitary Neuroendocrine Tumors: Prognostic Significance in Radiosurgery.",
"datePublished": "2023-07-25",
"url": "https://questionsmedicales.fr/article/37966247",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1227/neu.0000000000002607"
}
},
{
"@type": "ScholarlyArticle",
"name": "The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37462809",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-023-03449-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: new insights into anti-corticotroph antibody.",
"datePublished": "2023-11-14",
"url": "https://questionsmedicales.fr/article/38035072",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1284301"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sex differences in pituitary corticotroph excitability.",
"datePublished": "2023-07-18",
"url": "https://questionsmedicales.fr/article/37534368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fphys.2023.1205162"
}
},
{
"@type": "ScholarlyArticle",
"name": "An update on the genetic drivers of corticotroph tumorigenesis.",
"datePublished": "2024-06-03",
"url": "https://questionsmedicales.fr/article/38830604",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/a-2337-2265"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Cellules",
"item": "https://questionsmedicales.fr/mesh/D002477"
},
{
"@type": "ListItem",
"position": 3,
"name": "Cellules épithéliales",
"item": "https://questionsmedicales.fr/mesh/D004847"
},
{
"@type": "ListItem",
"position": 4,
"name": "Cellules corticotropes",
"item": "https://questionsmedicales.fr/mesh/D052680"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Cellules corticotropes - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Cellules corticotropes",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Cellules corticotropes",
"description": "Comment diagnostiquer une hyperplasie corticotrope ?\nQuels tests sont utilisés pour évaluer la fonction corticotrope ?\nQuels signes indiquent une tumeur corticotrope ?\nComment évaluer une insuffisance corticotrope ?\nQuel rôle joue l'imagerie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Cellules corticotropes",
"description": "Quels sont les symptômes d'un excès d'ACTH ?\nComment se manifeste une insuffisance corticotrope ?\nQuels signes cliniques sont associés à une tumeur corticotrope ?\nQuels symptômes psychologiques peuvent survenir ?\nComment l'hypercortisolisme affecte-t-il le corps ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Cellules corticotropes",
"description": "Peut-on prévenir les troubles liés aux cellules corticotropes ?\nComment réduire le stress pour protéger les corticotropes ?\nQuels modes de vie favorisent la santé des corticotropes ?\nY a-t-il des vaccinations pour prévenir les troubles hypophysaires ?\nComment le soutien psychologique aide-t-il ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Cellules corticotropes",
"description": "Quels traitements sont disponibles pour l'hypercortisolisme ?\nComment traiter une insuffisance corticotrope ?\nQuels médicaments sont utilisés pour inhiber l'ACTH ?\nQuelle est l'importance de la surveillance après traitement ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Cellules corticotropes",
"description": "Quelles complications peuvent survenir avec l'hypercortisolisme ?\nComment l'insuffisance corticotrope peut-elle affecter la santé ?\nQuels risques sont associés à la chirurgie des tumeurs corticotropes ?\nQuelles sont les conséquences d'un traitement inapproprié ?\nComment les complications affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Cellules corticotropes",
"description": "Quels facteurs augmentent le risque de tumeurs corticotropes ?\nComment le stress chronique influence-t-il les corticotropes ?\nY a-t-il des prédispositions hormonales aux troubles corticotropes ?\nQuel rôle joue l'âge dans les troubles corticotropes ?\nLes femmes sont-elles plus à risque que les hommes ?",
"url": "https://questionsmedicales.fr/mesh/D052680#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une hyperplasie corticotrope ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un dosage sanguin de l'ACTH et des tests d'imagerie comme l'IRM sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la fonction corticotrope ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests de stimulation à l'ACTH et les dosages de cortisol sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une tumeur corticotrope ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des maux de tête, des troubles visuels et une hypercortisolisme peuvent indiquer une tumeur."
}
},
{
"@type": "Question",
"name": "Comment évaluer une insuffisance corticotrope ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "On mesure les niveaux d'ACTH et de cortisol, souvent en réponse à un stress."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'imagerie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM permet de visualiser les anomalies de l'hypophyse et d'identifier les tumeurs."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'un excès d'ACTH ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la prise de poids, l'hypertension et des changements d'humeur."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une insuffisance corticotrope ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle se manifeste par fatigue, perte de poids, et hypotension orthostatique."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une tumeur corticotrope ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des troubles de la vision et des céphalées peuvent apparaître."
}
},
{
"@type": "Question",
"name": "Quels symptômes psychologiques peuvent survenir ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'anxiété, la dépression et des troubles de l'humeur peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment l'hypercortisolisme affecte-t-il le corps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il peut provoquer des changements métaboliques, une fragilité cutanée et des troubles osseux."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux cellules corticotropes ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un suivi médical régulier peut aider à détecter précocement."
}
},
{
"@type": "Question",
"name": "Comment réduire le stress pour protéger les corticotropes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques de gestion du stress comme la méditation et l'exercice peuvent être bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels modes de vie favorisent la santé des corticotropes ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée, l'exercice régulier et un sommeil adéquat sont essentiels."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations pour prévenir les troubles hypophysaires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de vaccinations spécifiques pour prévenir les troubles hypophysaires."
}
},
{
"@type": "Question",
"name": "Comment le soutien psychologique aide-t-il ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le soutien psychologique peut aider à gérer le stress et à prévenir des troubles hormonaux."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'hypercortisolisme ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les options incluent la chirurgie, la radiothérapie et des médicaments comme le kétoconazole."
}
},
{
"@type": "Question",
"name": "Comment traiter une insuffisance corticotrope ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement consiste en une thérapie de remplacement hormonale avec des glucocorticoïdes."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour inhiber l'ACTH ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme la cabergoline et le pasireotide peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la surveillance après traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La surveillance est cruciale pour ajuster le traitement et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des changements de poids."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'hypercortisolisme ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent le diabète, l'hypertension et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "Comment l'insuffisance corticotrope peut-elle affecter la santé ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut entraîner des crises surrénaliennes, mettant en danger la vie du patient."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à la chirurgie des tumeurs corticotropes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des saignements, des infections et des dommages aux tissus environnants."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'un traitement inapproprié ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un traitement inapproprié peut aggraver les symptômes et entraîner des complications graves."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent réduire la qualité de vie en provoquant des douleurs et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de tumeurs corticotropes ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et des mutations génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Comment le stress chronique influence-t-il les corticotropes ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut entraîner une surproduction d'ACTH et des troubles associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des prédispositions hormonales aux troubles corticotropes ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines conditions hormonales, comme le syndrome de Cushing, peuvent être prédisposantes."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'âge dans les troubles corticotropes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé peut augmenter le risque de développer des troubles hypophysaires."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque que les hommes ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines études montrent que les femmes sont plus susceptibles de développer des troubles corticotropes."
}
}
]
}
]
}
Molecular Genomics Core (MGC), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, United States.
Unit on Hypothalamic and Pituitary Disorders, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, United States.
There is conflicting evidence on the significance of adrenocorticotrophic hormone (ACTH) staining in the prognosis of nonfunctioning pituitary neuroendocrine tumors (NFpitNETs). The objective of this ...
This retrospective, multicenter study included patients managed with SRS for NFpitNET residuals. The patients were divided into 2 cohorts: (1) silent corticotroph (SC) for NFpitNETs with positive ACTH...
The cohort included 535 patients from 14 centers with 84 (15.7%) patients harboring silent corticotroph NFpitNETs (SCs). At last follow-up, local tumor progression occurred in 11.9% of patients in the...
In contemporary radiosurgical practice with a single fraction dose of 8-25 Gy (median 15 Gy), ACTH immunostaining in NFpitNETs did not appear to confer a significantly reduced rate of local tumor cont...
Data on silent corticotroph tumor (SCT) are still heterogeneous and controversial. In this study, we aimed to compare the demographic, clinicopathological manifestations, postoperative complications, ...
We searched PubMed and Web of Science for data of interest. Odds ratio (OR), mean difference (MD), hazard ratio (HR), and their 95% confidence intervals (CI) were pooled using the random-effect model....
Twenty-nine studies with 985 SCTs were included in meta-analyses. In comparison to other NFTs, SCTs were more commonly associated with female gender, younger age, cavernous sinus invasion, apoplexy, a...
SCT was demographically, clinicopathologically, and prognostically distinct from other NFTs and FCTs. These tumors should be considered high-risk; appropriate treatment decisions and more stringent fo...
A recently discovered facet of paraneoplastic adrenocorticotropic hormone (ACTH) deficiency exists in two forms: a paraneoplastic spontaneous isolated ACTH deficiency (IAD) and an immune checkpoint in...
We investigate circulating autoimmune autoantibodies in detail through a novel case of IAD that developed as a paraneoplastic autoimmune ACTH deficiency....
The patient developed IAD after 25 weeks of ICI therapy for metastasis of large-cell neuroendocrine carcinoma at 69 years of age. Ectopic ACTH expression and infiltration of CD3+, CD4+, CD8+, and CD20...
This case involved a combination of paraneoplastic spontaneously acquired IAD and ICI-related hypophysitis occupying the middle ground. Moreover, our study reveals new aspects of anti-POMC antibodies ...
Stress-related illness represents a major burden on health and society. Sex differences in stress-related disorders are well documented, with women having twice the lifetime rate of depression compare...
Clinical control of corticotroph tumors is difficult to achieve since they usually persist or relapse after surgery. Pasireotide is approved to treat patients with Cushing's disease for whom surgical ...
It was assessed cell viability, POMC expression and ACTH secretion in AtT20/D16v-F2 cells over- or under-expressing PRKCD....
We found that Pasireotide significantly reduces AtT20/D16v-F2 cell viability, POMC expression and ACTH secretion. In addition, Pasireotide reduces miR-26a expression. PRKCD silencing decreases AtT20/D...
Our results provide new insights into potential PRKCD contribution in Pasireotide mechanism of action and suggest that PRKCD might be a possible marker of therapeutic response in ACTH-secreting pituit...
Corticotroph pituitary neuroendocrine tumors (PitNETs) develop from ACTH-producing cells. They commonly cause Cushing's disease (CD), however, some remain clinically silent. Recurrent...
Study included 147 patients (100 CD and 47 silent tumors) that were screened for hot-spot mutations in...
We confirmed high prevalence of...
The introduction of intraoperative cytology revolutionized neurosurgical procedures in human medicine, providing real-time diagnostic guidance to surgeons and contributing to improved patient outcomes...
The aim of this study was to describe the cytologic features of pituitary adenomas in 12 dogs that underwent hypophysectomy....
The series included nine melanotroph adenomas and three corticotroph adenomas. Definitive diagnosis was based on histopathology and immunohistochemistry....
Cytologically, the adenomas had high numbers of bare nuclei and intact cells that were round to polygonal and situated individually or in small clusters. The intact cells had round to oval, eccentric ...
The results suggest that intraoperative cytology of canine pituitary adenomas holds promise as a valuable diagnostic tool, aiding swift differentiation from other sellar masses before histologic confi...
Spatial transcriptomic (ST) analysis of tumors provides a novel approach to studying gene expression along with the localization of tumor cells in their environment to uncover spatial interactions....
We present ST analysis of corticotroph pituitary neuroendocrine tumors (PitNETs) from formalin-fixed, paraffin-embedded tissues. ST data were compared to immunohistochemistry results. Gene expression ...
Seven tumors were used for ST analysis. In situ annotation of tumor tissue was inferred from the gene expression profiles and was in concordance with the annotation made by a pathologist. Furthermore,...
Together, our results provide the first attempt to clarify the spatial cell profile in PitNETs....